Research Alliance Corp IV (RACD) investor group reports 5.5% ownership of Class A shares

Rhea-AI Filing Summary

Research Alliance Corporation IV has a new large shareholder disclosure. Trails Edge Capital Partners LP, Trails Edge Biotechnology Master Fund LP and Ortav Yehudai report that, as of July 14, 2026, each may be deemed to beneficially own 500,000 Class A Ordinary Shares of the company. These 500,000 shares are held directly by Trails Edge Biotechnology Master Fund and represent 5.5% of the outstanding Class A Ordinary Shares, based on 9,098,529 shares outstanding as of July 13, 2026. For these shares, the filers report sole voting and sole dispositive power, with no shared power.

Key Figures

Beneficially owned shares: 500,000 Class A Ordinary Shares Ownership percentage: 5.5% Shares outstanding: 9,098,529 Class A Ordinary Shares +2 more

5 metrics

Beneficially owned shares 500,000 Class A Ordinary Shares Held directly by Trails Edge Biotechnology Master Fund LP as of July 14, 2026

Ownership percentage 5.5% Portion of outstanding Class A Ordinary Shares of Research Alliance Corporation IV

Shares outstanding 9,098,529 Class A Ordinary Shares Issued and outstanding as of July 13, 2026, per prospectus

Sole voting power 500,000 shares Shares over which the filers report sole power to vote

Sole dispositive power 500,000 shares Shares over which the filers report sole power to dispose

Key Terms

beneficially own, Class A Ordinary Shares, sole voting power, sole dispositive power, +1 more

5 terms

beneficially own financial

"each Filer may be deemed to beneficially own an aggregate of 500,000 Class A Ordinary Shares"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

Class A Ordinary Shares financial

"Title of class of securities: Class A Ordinary Shares, $0.0001 par value per share"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

sole voting power financial

"Sole power to vote or to direct the vote: 500,000.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole power to dispose or to direct the disposition of: 500,000.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

CUSIP Number financial

"CUSIP Number(s): G75228109"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/21/2026 - 04:15 PM Accepted by SEC EDGAR 07/21/2026 - 04:15 PM Learn about SEC filing dates

FAQ

What ownership stake in RACD does Trails Edge report?

Trails Edge entities and Ortav Yehudai report beneficial ownership of 500,000 Class A Ordinary Shares of RACD. This position represents 5.5% of the company’s outstanding Class A Ordinary Shares as of mid-July 2026, establishing them as a significant shareholder.

How many Research Alliance Corporation IV shares are outstanding?

The ownership report states that 9,098,529 Class A Ordinary Shares of RACD were issued and outstanding as of July 13, 2026. The reported 5.5% stake for Trails Edge and Ortav Yehudai is calculated based on this outstanding share count from the company’s prospectus.

Who holds the 500,000 RACD shares reported by Trails Edge?

The 500,000 RACD Class A Ordinary Shares are held directly by Trails Edge Biotechnology Master Fund LP. Trails Edge Capital Partners LP is the investment manager to this fund, and Ortav Yehudai, as Chief Investment Officer, exercises voting and investment discretion over these securities.

What level of voting power does Trails Edge have in RACD?

For the 500,000 RACD shares, the filers report sole voting power and sole dispositive power over all shares, with no shared voting or dispositive power. This means decisions on how these shares are voted and whether they are sold rest solely with the reporting group.

On what date is the reported RACD ownership effective?

The beneficial ownership is reported as of July 14, 2026, referred to as the Event Date. The 5.5% ownership percentage is calculated using the 9,098,529 shares outstanding as of July 13, 2026, as disclosed in the company’s prospectus.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Research Alliance Corporation IV

(Name of Issuer)

Class A Ordinary Shares, $0.0001 par value per share

(Title of Class of Securities)

G75228109

(CUSIP Number)

07/14/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): G75228109

1

Names of Reporting Persons

Trails Edge Capital Partners, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 500,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 500,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

500,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

IA, PN

Comment for Type of Reporting Person: See Item 4 for additional information.

SCHEDULE 13G

CUSIP Number(s): G75228109

1

Names of Reporting Persons

Trails Edge Biotechnology Master Fund, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 500,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 500,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

500,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: See Item 4 for additional information.

SCHEDULE 13G

CUSIP Number(s): G75228109

1

Names of Reporting Persons

Ortav Yehudai

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 500,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 500,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

500,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: See Item 4 for additional information.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Research Alliance Corporation IV
(b)	Address of issuer's principal executive offices: 600 Fifth Avenue, 23rd Floor, New York, NY 10020
Item 2.
(a)	Name of person filing: This report on Schedule 13G is being filed by Trails Edge Capital Partners, LP, a Delaware limited partnership ("Trails Edge Capital"), Trails Edge Biotechnology Master Fund, LP, a Cayman Islands limited partnership ("Trails Edge Biotechnology"), and Ortav Yehudai ("Mr. Yehudai"). Trails Edge Capital is the investment manager to Trails Edge Biotechnology, and Mr. Yehudai is the Chief Investment Officer of Trails Edge Capital. Each of Trails Edge Capital, Trails Edge Biotechnology and Mr. Yehudai are referred to individually as a "Filer" and collectively as the "Filers".
(b)	Address or principal business office or, if none, residence: The address for each Filer is 3455 Peachtree Road NE, Suite 900, Atlanta, GA 30326.
(c)	Citizenship: See Item 4 of the cover page of each Filer.
(d)	Title of class of securities: Class A Ordinary Shares, $0.0001 par value per share
(e)	CUSIP Number(s): G75228109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of July 14, 2026 (the "Event Date"), each Filer may be deemed to beneficially own an aggregate of 500,000 Class A Ordinary Shares, $0.0001 par value per share (the "Ordinary Shares"), of Research Alliance Corporation IV (the "Issuer"). The 500,000 Ordinary Shares reported as beneficially owned on this Schedule 13G by each Filer consist of 500,000 Ordinary Shares held directly by Trails Edge Biotechnology. As a result, Trails Edge Biotechnology beneficially owns 5.5% of the outstanding Ordinary Shares of the Issuer as of the Event Date. Trails Edge Capital, as the investment manager to Trails Edge Biotechnology, may be deemed to beneficially own these securities. Mr. Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own 5.5% of the outstanding Ordinary Shares of the Issuer as of the Event Date. Ownership percentages are based on 9,098,529 Ordinary Shares issued and outstanding as of July 13, 2026, as reported by the Issuer in its Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on July 13, 2026.
(b)	Percent of class: 5.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 500,000.00
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 500,000.00
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Trails Edge Capital Partners, LP

Signature:	/s/ Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai
Name/Title:	Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC
Date:	07/21/2026

Trails Edge Biotechnology Master Fund, LP

Signature:	/s/ Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai
Name/Title:	Ortav Yehudai / Chief Investment Officer of Trails Edge GP, LLC
Date:	07/21/2026

Ortav Yehudai

Signature:	/s/ Ortav Yehudai
Name/Title:	Ortav Yehudai / Individual
Date:	07/21/2026

Exhibit Information

Exhibit 1- Joint Filing Agreement